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Abstract——In 2005, the International Union of Basic
and Clinical Pharmacology Committee on Receptor
Nomenclature and Drug Classification (NC-IUPHAR)
published a catalog of all of the human gene sequences
known or predicted to encode G protein-coupled
receptors (GPCRs), excluding sensory receptors. This
review updates the list of orphan GPCRs and describes
the criteria used by NC-IUPHAR to recommend the
pairing of an orphan receptor with its cognate ligand(s).
The following recommendations are made for new
receptor names based on 11 pairings for class A GPCRs:
hydroxycarboxylic acid receptors [HCA1 (GPR81)
with lactate, HCA2 (GPR109A) with 3-hydroxybutyric
acid, HCA3 (GPR109B) with 3-hydroxyoctanoic acid];
lysophosphatidic acid receptors [LPA4 (GPR23), LPA5
(GPR92), LPA6 (P2Y5)]; free fatty acid receptors [FFA4
(GPR120) with omega-3 fatty acids]; chemerin receptor
(CMKLR1; ChemR23) with chemerin; CXCR7 (CMKOR1)
with chemokines CXCL12 (SDF-1) and CXCL11 (ITAC);
succinate receptor (SUCNR1) with succinate; and
oxoglutarate receptor [OXGR1 with 2-oxoglutarate].
Pairings are highlighted for an additional 30 receptors
in class A where further input is needed from the
scientific community to validate these findings. Fifty-
seven human class A receptors (excluding pseudogenes)
are still considered orphans; information has been
ABBREVIATIONS: Ang-(1-7), angiotensin-(1–7); BAM22, bovine adrenal medulla peptide 22; CMKLR1, chemokine-like receptor 1; CysLT,
cysteinyl leukotriene; ERK, extracellular signal–regulated kinase; FFA, free fatty acid; GLP-1, glucagon-like peptide-1; GPCR, G protein-
coupled receptor; HCA, hydroxycarboxylic acid; 12-(S)-HETE, 12-(S)-hydroxyeicosatetraenoic acid; ID no., identification number; ITAC,
interferon-inducible T-cell a chemoattractant; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; LysoPS, lysophosphatidylserine;
MRG, Mas-related GPCR; NAGly, N-arachidonoylglycine; NC-IUPHAR, International Union of Basic and Clinical Pharmacology Committee
on Receptor Nomenclature and Drug Classification; 7a,25-OHC, 7a,25-dihydroxycholesterol; PAMP-20, proadrenomedullin N-terminal 20
peptide; RvD1, resolvin D1; S1P, sphingosine 1-phosphate; SDF-1, stromal cell–derived factor-1.
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provided where there is a significant phenotype in
genetically modified animals. In class B, six pairings
have been reported by a single publication, with 28
(excluding pseudogenes) still classified as orphans.
Seven orphan receptors remain in class C, with one
pairing described by a single paper. The objective is
to stimulate research into confirming pairings of
orphan receptors where there is currently limited
information and to identify cognate ligands for the
remaining GPCRs. Further information can be found
on the IUPHAR Database website (http://www.iuphar-db.
org).
I. Introduction
The sequencing of the human genome has allowed
the IUPHAR (International Union of Basic and Clinical
Pharmacology) Committee on Receptor Nomenclature
and Drug Classification (NC-IUPHAR) to catalog all
of the human gene sequences potentially encoding G
protein-coupled receptors (GPCRs), excluding sensory
receptors. In addition to established transmitter systems,
the classification in Pharmacological Reviews (see Foord
et al., 2005) and in the IUPHAR Database (IUPHAR-DB)
(see Sharman et al., 2011) included “orphan” GPCRs for
which the endogenous ligand(s) was not known. Since this
publication, considerable progress has been made in
screening artificially expressed receptors to identify the
cognate endogenous ligand (for example, see Zhang et al.,
2011; Civelli, 2012; Yoshida et al., 2012). Where un-
derstanding of the physiology, pharmacology, and patho-
logy has begun to emerge, the receptor has been officially
classified and named (usually after the endogenous ligand
following IUPHAR nomenclature conventions) and pub-
lished in Pharmacological Reviews (http://www.iuphar-db.
org/nciupharPublications.jsp). Physiologic functions have
now been assigned to a number of receptors previously
designated as orphans. These include the family of free
fatty acid receptors (FFA1–FFA3) (Stoddart et al., 2008);
neuropeptide B and W as ligands NPBW1 (GPR7) and
NPBW2 (GPR8) (Singh and Davenport, 2006); the protein
encoded by the APJ gene (Ishida et al., 2004), now
classified as the apelin receptor (Pitkin et al., 2010);
GPR30 as the estrogen GPCR (GPER) (Revankar et al.,
2005; Thomas et al., 2005; Wang et al., 2008; Martensson
et al., 2009; Prossnitz and Barton, 2011); GPR54 as
the kisspeptin receptor (Kirby et al., 2010); GHS-R1a
as the ghrelin receptor (Davenport et al., 2005); the
TA1 receptor activated by endogenous trace amine
ligands, including tyramine (IUPHAR-DB no. 2150) and
b-phenylethylamine (IUPHAR-DB no. 2144) (Maguire
et al., 2009); and GPR131 as the bile acid receptor
(GPBA) (Maruyama et al., 2002). This review extends the
number of receptors where these criteria have been met,
particularly where replicated by independent groups,
which are shown for class A GPCRs in Table 1.
To reflect the dynamic nature of the field, where
a single paper exists describing a new pairing, a list is
maintained on IUPHAR-DB (http://www.iuphar-db.org/
latestPairings.jsp) (Table 2). This review also reports on
a third group still considered orphans (Table 3). In a small
number of instances, the pairing is retracted because it
cannot be repeated. In some cases, “surrogate” ligands for
orphan GPCRs (drugs or small molecules that can be
used as tool compounds that act on targets for which the
endogenous ligand is not yet known) have been identified,
and these can be used as pharmacological tools to explore
the function and therapeutic potential of these proteins.
The alternative approach is to focus on significant phe-
notypes in genetically modified animals, and this in-
formation has been included. Orphan GPCRs have been
identified that have activity in the absence of an en-
dogenous ligand or work in concert with other receptors
and may not have a cognate endogenous ligand. Finally,
a small number of genes are listed, initially identified as
orphan GPCRs, which are pseudogenes, at least in some
individuals.
Thirty human receptors in class A are currently
supported by a single publication; or where there is
more than one independent publication, the results are
not concordant or relevant committees are waiting for
the accumulation of unequivocal pharmacological evi-
dence for a formal adoption of nomenclature. Fifty-seven
receptors (excluding pseudogenes) are still considered
orphans. In class B, six pairings have been reported by
a single publication, with an additional 28 (excluding
pseudogenes) still classified as orphans. Seven orphan
receptors remain in class C, with one pairing described
by a single paper.
A number of orphan GPCRs were able to be deorphan-
ized because of their close similarity to other receptors or
paralogs. These are thought to have arisen by gene
duplication and might therefore be expected to have
similar ligands. Some of the receptors described in this
review are groups of paralogs such as GPR3, GPR6, and
GPR12. Conversely, however, GPCRs with disparate
evolutionary origins can bind and respond to the same
ligands. For example, the relaxins are able to activate
RXFP1 and -2, which are 757 and 737 amino acids in
length and share ;60% amino acid sequence similarity,
with 10 leucine-rich repeats in their large N-terminal
extracellular domains. In contrast, RXFP3 and -4, which
are also activated by relaxins, have short N-terminal
extracellular domains and contain only 469 and 374
amino acid residues. Receptors have been listed al-
phabetically in the tables, and reviews (including
Lagerström and Schiöth, 2008; Strotmann et al., 2011)
should be consulted for detailed analysis of the phyloge-
netic relationships.
We have endeavored to identify all key papers
reporting pairings by carrying out systematic searches,
using current as well as previous gene names for the
orphan receptors in classes A, B, and C as they appear
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in the IUPHAR-DB. It is not possible to include all
papers that refer to some aspect of a particular orphan
receptor, but where appropriate and where they exist,
we have added selected references to more detailed
reviews, which should be consulted for further informa-
tion. To provide readers with access to a wide range of
chemical information and the biologic activity data for
the ligands listed in this review, IUPHAR-DB Ligand
identification numbers (ID no.) are provided (within
parentheses). Readers may either enter the Ligand
ID no. into the “Quick text search” box on the IUPHAR-DB
website (http://www.iuphar-db.org) or navigate to the
ligand search tools page (http://www.iuphar-db.org/
DATABASE/chemSearch.jsp) and select “IUPHAR/GRAC
Ligand ID” in the “Chemical identifier” search box. The
review excludes sensory receptors, which are curated by
the Olfactory Receptor DataBase (ORDB) (http://senselab.
med.yale.edu/ordb/).
II. Criteria for Deorphanization
Several criteria are used by NC-IUPHAR in considering
the assignment of an endogenous ligand to a receptor.
Firstly, two or more refereed papers from independent
research groups should demonstrate activity of the ligand
at the receptor, with a potency that is consistent with
a physiologic function. Reproducibility of the pairing is the
minimum criterion, particularly to avoid false positives
that might arise in high-throughput screens or for other
reasons. In some cases, although two independent groups
have reported a pairing, others have failed to reproduce
this. We have indicated where pairings remain controver-
sial to identify areas where more research is required for
NC-IUPHAR to make a definitive statement and that are
under active consideration by the relevant subcommittees.
Occasionally, reported pairings are retracted, and these
are recorded on the IUPHAR-DB (http://www.iuphar-db.
org/latestPairings.jsp).
As a particular field evolves, the following additional
criteria may support and strengthen the initial pairing,
although it is recognized that these are exacting and
are unlikely to be met in all instances. Preferably, both
radioligand binding (although it is recognized that
some endogenous ligands may not be suitable for
labeling or the density of receptors may be too low to
detect) and functional assays should be employed, both
in vitro and in native tissues. Selective agonists should
mimic and selective antagonists should block the
action of the endogenous ligand. Secondly, the putative
endogenous ligand should be present in tissues in
appropriate concentrations. Further evidence for the
pairing of orphan GPCRs with cognate endogenous
ligands may be obtained at the anatomic level; there
should be plausible mechanisms for the proposed ligand to
reach physiologically significant concentrations in tissues
expressing its cognate receptor, either through local
synthesis or by transport to the tissue, e.g., as a hormone.
For neuropeptides, indirect techniques such as immuno-
cytochemistry and in situ hybridization of the precursor
mRNA can provide useful evidence. Small molecules that
are candidate ligands for receptors may be detected using
a variety of techniques including radioimmunoassay and
mass spectrometry associated with gas chromatography
or high-performance liquid chromatography. Deleting the
gene encoding the receptor in mice, exploiting a naturally
occurring deletion in human tissues, or RNA silencing
should abolish receptor characteristics, such as radio-
ligand binding or physiologic/pharmacological actions of
the endogenous ligand in functional assays. Conversely,
receptor overexpression may be expected to potentiate
these actions.
Many of the recently proposed ligands are lipids, which
pose distinct difficulties for assignation as endogenous
orthosteric ligands. Firstly, concentration-response rela-
tionships are almost always difficult to assess due to
detergent and surfactant effects, binding to proteins such
as albumin, and formation of micelles. Secondly, by
modification of membrane properties or insertion into
membranes, lipids can block or reveal the effects of
allosteric modulators; membrane interactions can also
TABLE 1
Recommendations for formal receptor nomenclature based on new pairings of class A orphan receptors with cognate ligands
Gene symbols are those approved by the HUGO Gene Nomenclature Committee (http://www.genenames.org/) (Seal et al., 2011). Where the phenotype of the knockout
mouse has been published, this is indicated: Further information can be obtained from the IUPHAR Database (http://www.iuphar-db.org/) (Sharman et al., 2011) and the
Mouse Genome Database at Mouse Genome Informatics (Eppig et al., 2012).
Endogenous Ligand Official IUPHARNomenclature
Previous
Nomenclature
Approved
Human
Gene Symbol
Knockout
Mouse
Phenotype
Reported
Chemerin (RARRES2, resolvin E1, TIG2) Chemerin CMKLR1 CMKLR1 Yes Yes
CXCL12 (SDF-1), CXCL11 (ITAC) CXCR7 CMKOR1 CXCR7 Yes Yes
Omega-3 fatty acids FFA4 GPR120/GPR129 O3FAR1 Yes Yes
Lactate HCA1 GPR81/GPR104 HCAR1 Yes Yes
D-b-Hydroxybutyrate HCA2 GPR109A HCAR2 Yes Yes
3-Hydroxyoctanoate HCA3 GPR109B HCAR3
a No
LPA LPA4 GPR23 LPAR4 Yes Yes
LPA LPA5 GPR92/GPR93 LPAR5 Yes Yes
LPA LPA6 P2RY5 LPAR6 No
2-Oxoglutarate Oxoglutarate GPR91 OXGR1 No
Succinate Succinate GPR99 SUCNR1 Yes Yes
a Gene absent in mice.
970 Davenport et al.
drive allosteric changes in receptor conformation and
also change the surface charge around channels and
receptors. Studies of the crystal structure of the S1P1
receptor fused to T4 lysozyme in complex with an
antagonist sphingolipid mimic have been particularly
instructive (Hanson et al., 2012). Lipid ligands are
thought to gain access to the binding pocket from
within the membrane bilayer rather than from the
extracellular compartment.
In parallel, there has been a major revolution in lipid
metabolomics, with up to 3000 lipids being detectable
in small biologic membrane samples, and precise
changes of these lipids may be followed in, for example,
pathologic situations. However, this expensive meth-
odology has not been applied to any of the studies
claiming lipids as the endogenous agonists of receptors,
so the question of whether closely related lipids may
be more preponderant (and active) than the studied
species is a clear concern for nomenclature. NC-IUPHAR
will continue to apply the criteria for evaluating pairing
of lipids with GPCRs that are used for non-lipid ligands
but encourages authors to take these reservations into
account for future studies.
In the absence of a cognate endogenous ligand,
genetically modified mice and overexpression of genes
encoding target receptors can provide evidence for
a physiologic or pathophysiological role. For example,
the GPR3 gene has been mapped to the candidate
Alzheimer’s disease linkage region and is predomi-
nantly expressed in the central nervous system. It is
thought to be a constitutively active orphan GPCR and
has been identified as a modulator of amyloid-b pro-
duction. Overexpression of GPR3 stimulated amyloid-b
production in an Alzheimer’s disease mousemodel, where-
as knocking out the GPR3 gene prevented accumula-
tion of the amyloid-b peptide (Thathiah et al., 2009).
TABLE 2
Reported pairings of orphan receptors with cognate ligands reported by a single paper
Gene symbols are those approved by the HUGO Gene Nomenclature Committee (http://www.genenames.org/) (Seal et al., 2011). Where the
phenotype of the knockout mouse has been published, this is indicated: Further information can be obtained from the IUPHAR Database (http://
www.iuphar-db.org/) (Sharman et al., 2011) and the Mouse Genome Database at Mouse Genome Informatics (Eppig et al., 2012).
Putative Endogenous Ligand Approved HumanGene Symbol Knockout Mouse Phenotype Reported
Class A
Chemerin GPR1 Yes No
S1P GPR3 Yes Yes
Protons GPR4 Yes Yes
S1P GPR6 Yes Yes
S1P GPR12 Yes Yes
Nucleotides and CysLTs (leukotriene C4, leukotriene
D4, UDP, UDP-galactose)
GPR17 Yes Yes
NAGly GPR18 No
12-(S)-HETE GPR31a No
RvD1 GPR32a No
LPS GPR34 Yes Yes
Kynurenic acid, 2-acyl LPA GPR35 No
Neuropeptide head activatorb GPR37 Yes Yes
Zn2+ GPR39 Yes Yes
L-a-LPI GPR55 Yes Yes
Protons GPR65 Yes Yes
Protons GPR68 Yes Yes
CCL5 (RANTES) GPR75 No
Medium-chain fatty acids GPR84 Yes Yes
LPA GPR87 Yes Yes
Oleoylethanolamide GPR119 Yes Yes
Protons GPR132 Yes Yes
Oxysterols GPR183 Yes Yes
R-spondins LGR4 Yes Yes
R-spondins LGR5 Yes Yes
R-spondins LGR6 No
Ang-(1-7) MAS1 Yes Yes
b-Alanine MRGPRD Yes Yes
BAM22 MRGPRX1c No
Cortistatin, PAMP MRGPRX2c No
LPA, S1P P2RY10 No
Class B
Phosphatidylserine BAI1 No
C1q-like proteins BAI3 No
Decay accelerating factor CD97 Yes No
Collagen type III GPR56 Yes Yes
Neurexins, teneurin-2 LPHN1 Yes Yes
FLRT3 LPHN3 Yes No
Class C
Calcium, amino acids, and osteocalcin GPRC6A Yes Yes
a Pseudogene in mice.
b See discussion in text as to whether neuropeptide head activator is an endogenous ligand.
c Gene absent in mice.
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The results suggest that the GPR3 protein may be
a potential therapeutic target for the treatment of
Alzheimer’s disease, leading to the development of
surrogate ligands in the absence of knowledge of the
endogenous transmitter (Thathiah et al., 2009).
III. Recommendations for Formal Receptor
Nomenclature Based on New Pairings of Orphan
Receptors with Cognate Ligands
A. Class A
1. Hydroxycarboxylic Acid Receptors: HCA1 (GPR81)/
Lactate, HCA2 (GPR109A)/3-Hydroxybutyric Acid, and
HCA3 (GPR109B)/3-Hydroxyoctanoic Acid. A family
of three structurally related receptors has been named
the hydroxycarboxylic acid (HCA) receptors (Offermanns
et al., 2011). HCA1 (GPR81) is activated by lactic acid
(IUPHAR-DB ID nos. 2932, 2934) (Cai et al., 2008;
Ahmed et al., 2010), HCA2 (GPR109A; also known as
PUMA-G) by b-D-hydroxybutyric acid (IUPHAR-DB
ID no. 1593) (Taggart et al., 2005), and HCA3 (GPR109B;
also known as HM74) is activated by the b-oxidation
intermediate 3-hydroxyoctanoic acid (IUPHAR-DB ID
no. 2933) (Ahmed et al., 2009). The endogenous li-
gands of these receptors are unusual as they are of
relatively low potency (in the millimolar range) com-
pared with other endogenous GPCR ligands, although
the endogenous ligand of HCA3 (3-hydroxyoctanoic
acid) activates its receptor at micromolar concentra-
tions. HCA2 and HCA3 are also activated by nicotinic
TABLE 3
Orphan receptors
Gene symbols are those approved by the HUGO Gene Nomenclature Committee
(http://www.genenames.org/) (Seal et al., 2011). Where the phenotype of the knockout
mouse has been published, this is indicated: Further information can be obtained
from the IUPHAR Database (http://www.iuphar-db.org/) (Sharman et al., 2011) and
the Mouse Genome Database at Mouse Genome Informatics (Eppig et al., 2012).
Approved Human
Gene Symbol Knockout Mouse Phenotype Reported
Class A
BB3 Yes Yes
GPR15 No
GPR19 Yes Yes
GPR20 Yes No
GPR21 Yes No
GPR22 Yes Yes
GPR25 No
GPR26 Yes Yes
GPR27 No
GPR33a No
GPR37L1 Yes Yes
GPR42b,c No
GPR45 No
GPR50 Yes Yes
GPR52 No
GPR61 Yes No
GPR62 No
GPR63 No
GPR78 Nob b
GPR79c Nod d
GPR82 Yes Yes
GPR83 Yes No
GPR85 Yes Yes
GPR88 Yes Yes
GPR101 No
GPR135 No
GPR139 No
GPR141 No
GPR142 No
GPR146 No
GPR148b No
GPR149 Yes Yes
GPR150 No
GPR151 Yes No
GPR152 No
GPR153 No
GPR160 No
GPR161 Yes No
GPR162 No
GPR171 No
GPR173 No
GPR174 No
GPR176 No
GPR182 No
MAS1Lb No
MRGPRE Yes Yes
MRGPRF No
MRGPRG No
MRGPRX3 Nod
MRGPRX4b No
OPN3 No
OPN5 No
P2RY8b No
TAAR2 No
TAAR3c No
TAAR4Pc No
TAAR5 No
TAAR6 No
TAAR8 No
TAAR9 No
Class B
BAI2 Yes Yes
CELSR1 Yes Yes
CELSR2 Yes Yes
CELSR3 Yes Yes
ELTD1 Yes No
EMR1 Yes Yes
EMR2b No
(continued )
TABLE 3—Continued
Approved Human
Gene Symbol Knockout Mouse Phenotype Reported
EMR3b No
EMR4Pc No
GPR64 Yes Yes
GPR97 Yes No
GPR98 Yes Yes
GPR110 No
GPR111 No
GPR112 No
GPR113 No
GPR114 No
GPR115 No
GPR116 No
GPR123 No
GPR124 Yes Yes
GPR125 Yes No
GPR126 Yes Yes
GPR128 No
GPR133 No
GPR144 No
GPR157 No
LPHN2 No
Class C
GPR156 No
GPR158 No
GPR179 Yes Yes
GPRC5A Yes Yes
GPRC5B Yes Yes
GPRC5C Yes No
GPRC5D No
a Pseudogene in most individuals.
b Gene absent in rats and mice.
c Pseudogene in man.
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acid (Tunaru et al., 2003). This receptor family was first
named the nicotinic acid receptor family. However, this
nomenclature is inappropriate because nicotinic acid is
not an endogenous ligand. HCA1 and HCA2 are present
in humans and rodents, whereas HCA3 is probably the
result of a recent gene duplication of the HCA2 receptor
and is only present in primates. All three receptors are
particularly highly expressed in adipocytes, where they
are thought to couple to Gi proteins to cause antilipolytic
effects. This has led to the development of a number of
synthetic agonists, albeit of comparatively low affinity,
that induce antidyslipidemic effects similar to those of
nicotinic acid, the original surrogate ligand for HCA2.
However, recently Lauring et al. (2012) found that
synthetic agonists of HCA2 receptor do not fully mimic
the lipid effects of nicotinic acid. Other pharmacolog-
ical tools are limited. There are currently no selective
antagonists or allosteric modulators for any of these
receptors.
2. Lysophosphatidic Acid Receptors: LPA4 (GPR23),
LPA5 (GPR92), and LPA6 (P2Y5). Lysophosphatidic acid
(LPA; IUPHAR-DB ID no. 2906) is a membrane-derived
lipid, which mediates its actions via a cluster of three
structurally related GPCRs, LPA1–3. These receptors
mediate a wide range of physiologic actions. Recently, two
structurally dissimilar receptors, previously designated
as orphans, have been added to the LPA receptor family.
They bind LPA with high affinity (Chun et al., 2010),
despite having closer sequence similarity to P2Y recep-
tors. This suggests evolution of LPA responsiveness via
two lineages.GPR23 (also known as P2Y9 and P2Y5-like)
is activated by LPA (IUPHAR-DB ID no. 2906) (Noguchi
et al., 2003) and has been classified as LPA4. The receptor
is present in humans, rats, and mice and, interest-
ingly, is located on the X chromosome in each species.
The receptor is reported to couple to multiple G proteins
(G12/13, Gq/11, Gi, and Gs). Agonists and antagonists se-
lective for LPA4 over other LPA receptors have not been
developed. One group reported that LPA4 receptor–
deficient mice displayed no overt abnormalities but that
LPA4-deficient mouse embryonic fibroblasts were hyper-
sensitive to LPA-induced cell migration, suggesting that
the receptor is a suppressor of LPA-dependent cell mi-
gration and invasion (Lee et al., 2008b). A second group
(Sumida et al., 2010) showed that a subset of LPA4-
deficient embryos did not survive gestation and displayed
hemorrhages and/or edema in many organs, concluding
that LPA4 regulates establishment of the structure and
function of blood and lymphatic vessels during mouse
embryogenesis.
The orphan receptor GPR92 has been classified as
LPA5, which is activated by LPA (IUPHAR-DB ID no.
2906) (Kotarsky et al., 2006; Lee et al., 2006). Agonists
and antagonists selective for LPA5 over other LPA
receptors have not been developed, although there
appears a preference for ether LPA analogs over ester
LPA analogs (Williams et al., 2009) and targeted
disruption of the LPA5 gene causes a pain phenotype
(Lin et al., 2012).
The gene initially termed 6H1 (Kaplan et al., 1993)
was subsequently renamed P2RY5 due to sequence
homology with P2Y receptors (Webb et al., 1996). LPA
(IUPHAR-DB ID no. 2906) was proposed as a ligand for
P2Y5 (Pasternack et al., 2008; Yanagida et al., 2009).
Pasternack et al. (2008) identified homozygous trun-
cating mutations in the P2RY5 (now LPAR6) gene and
found the receptor to be essential for the maintenance
of human hair growth. We recommend P2Y5 be classified
as LPA6.
3. FFA4 (GPR120) and Omega-3 Fatty Acids.
FFAs are essential nutritional components and, in
addition, activate a family of three GPCRs (FFA1–
FFA3), which play critical roles in physiology and
pathophysiology, particularly in metabolic disorders.
GPR120 is abundantly expressed in intestine and
functions as a receptor for saturated and unsaturated
long-chain FFAs including palmitoleic acid, a-linolenic
acid (IUPHAR-DB ID no. 1049), and docosahexae-
noic acid (IUPHAR-DB ID no. 1051) linked to the
Gq/11 pathway (Hirasawa et al., 2005). The authors
showed that the main physiologic action of GPR120
by FFAs was the secretion of glucagon-like peptide-1
(GLP-1) in vitro and in vivo and an increase in cir-
culating insulin. This has important therapeutic impli-
cations, as GLP-1 is the most potent insulinotropic
incretin.
GPR120-deficient mice fed high-fat diets developed
obesity, glucose intolerance, and fatty liver with de-
creased adipocyte differentiation and lipogenesis and
enhanced hepatic lipogenesis. Conversely, in humans,
GPR120 expression in adipose tissue is significantly
higher in obese individuals than in lean controls, owing
to a deleterious nonsynonymous mutation that inhibits
GPR120 signaling activity. Furthermore, this variant
increased the risk of obesity in European populations.
The authors of this study (Ichimura et al., 2012)
concluded that these studies show that dysfunction of
GPR120 leads to obesity in both mouse and man.
However, further studies are required to understand
these apparently contradictory results.
GPR120 knockout mice (as well as FFA1 receptor
knockout mice) showed a diminished taste preference
for linoleic acid and oleic acid and diminished neuro-
physiological responses to several fatty acids, showing
that FFA1 and GPR120mediate the taste of fatty acids
(Cartoni et al., 2010). We recommend GPR120 be
classified as FFA4.
4. The Chemerin Receptor (Chemokine-like Receptor;
CMKLR1; ChemR23) and Chemerin. Wittamer et al.
(2003) first identified chemerin (IUPHAR-DB ID no.
2945), a potent 14-kDa chemoattractant protein of
a novel class, in biological fluids as the product of the
human tazarotene-induced gene-2 (Tig-2; current gene
symbol, RARRES2). It is secreted in the plasma as a
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precursor of low biologic activity, which upon proteolytic
cleavage of its COOH-terminal domain is converted to an
agonist of CMKLR1 (Luangsay et al., 2009), the chemerin
receptor. The pairing was confirmed by Meder et al.
(2003) and Zabel et al. (2005). Chemerin, acting via this
receptor, induces the migration of macrophages and
dendritic cells in vitro, suggesting a proinflammatory
role, whereas in vivo studies using chemerin receptor–
deficient mice suggest an anti-inflammatory action
(Luangsay et al., 2009). Responses to chemerin that are
abolished in receptor knockout mice include migration of
dendritic cells and macrophages (Luangsay et al., 2009;
Bondue et al., 2011a), adhesion of peritoneal exudate
cells to fibronectin (Hart and Greaves, 2010), and en-
hancement of microbial particle clearance and apoptotic
neutrophil ingestion by macrophages (Cash et al., 2010).
Chemerin/CMKLR1 interaction also promotes adipo-
genesis and angiogenesis (for review, see Yoshimura
and Oppenheim, 2011). We recommend CMKLR1 be
classified as the chemerin receptor.
Resolvins are a family of potent lipid mediators
derived from both eicosapentaenoic acid (IUPHAR-DB
ID no. 3362) and docosahexaenoic acid (IUPHAR-DB
ID no. 1051) (see Uddin and Levy, 2011). Resolvin E1
(IUPHAR-DB ID no. 3333), a potent anti-inflammatory
and proresolving mediator derived from eicosapentae-
noic acid generated during the resolution phase of
inflammation, has also been reported as a ligand for
the chemerin receptor (Arita et al., 2007). To date, this
pairing has not been confirmed, and another group has
failed to reproduce the activity of resolvin E1 on the
chemerin receptor in binding and a range of functional
assays (Bondue et al., 2011b).
5. CXCR7 (CMKOR1) with CXCL12 (SDF-1) and
CXCL11 (ITAC). The chemokines stromal cell-derived
factor-1 (SDF-1), also known as chemokine (C-X-C motif)
ligand 12 (CXCL12), and interferon-inducible T-cell a
chemoattractant (ITAC), also known as CXCL11, bind
with high affinity to CXCR7 and promote cell migration
(Balabanian et al., 2005; Burns et al., 2006). CXCR7 does
not signal through classic G protein-coupled mechanisms
and has been proposed to function as a nonsignaling
receptor that either mediates CXCL12 internalization
and degradation or forms heterodimers with CXCR4
to modify CXCR4 downstream signaling (Zhu and
Murakami, 2012). However, there is now convincing evi-
dence that CXCR7 is a functional receptor, signaling
through b-arrestin to activate mitogen-activated protein
kinases (Rajagopal et al., 2010; Zhu and Murakami,
2012). Intriguingly, in zebrafish, CXCR7 has been
shown to shape gradients of CXCL12 for optimal sig-
naling at CXCR4 to mediate gonadal germ cell migra-
tion (Boldajipour et al., 2008). The phenotype of CXCR7-
deficient mice included postnatal lethality and cardio-
vascular defects (Sierro et al., 2007; Gerrits et al., 2008).
6. Succinate Receptor (SUCNR1 GPR91) with Succi-
nate; Oxoglutarate Receptor (OXGR1 GPR99) with
2-Oxoglutarate (a-Ketoglutarate). Succinate (IUPHAR-DB
ID no. 3637) and 2-oxoglutarate (a-ketoglutaric acid;
IUPHAR-DB ID no. 3636) are intermediates of the citric
acid cycle present at micromolar concentrations in blood
and are regulated by respiration, metabolism, and renal
mechanisms. He et al. (2004) proposed that SUCNR1
(GPR91) functions as a receptor for succinate, with
an EC50 of 56 mM in an aequorin assay, coupling to a
pertussis toxin–sensitive Gi/Go and pertussis toxin–
insensitive Gq pathways. They also proposed another
closely related GPCR, OXGR1 (GPR99), to be acti-
vated by 2-oxoglutarate, with an EC50 of 70 mM via a
Gq-mediated pathway. Both pairings have been repli-
cated in a b-arrestin assay (Southern et al., 2013), also
at high EC50 values of 800 mM for succinate binding to
SUCNR1 and 130 mM for 2-oxoglutarate binding to
OXGR1. In Gpr91 knockout mice, there was an im-
pairment in renin release from the kidney in response to
high glucose levels, thought to be mediated by a para-
crine signaling pathway involving accumulation of
succinate and activation of GPR91 (Toma et al., 2008).
Consistent with this, succinate increased blood pressure
in rats and mice—an effect abolished in Gpr91-deficient
mice (He et al., 2004). We recommend SUCNR1 be
classified as the succinate receptor, and OXGR1 be
classified as the oxoglutarate receptor.
B. Class B
No recommendations.
C. Class C
No recommendations.
IV. Pairings of Orphan Receptors with Cognate
Ligands Reported by a Single Paper or Where
a Formal Pairing Is Yet To Be Agreed
The following is a list of 32 receptors for which single
publications have claimed to identify the endogenous
ligand; alternatively, input from the scientific commu-
nity is needed to reproduce and validate these findings.
The minimum criterion for NC-IUPHAR to recommend
that an orphan receptor receives official recognition is
that the pairing of the ligand with the receptor should
be repeated by at least one independent laboratory,
with no overlap between the researchers, ideally by
a different assay. The majority of papers discussed
below have used artificially expressed receptors linked
to a reporter system; the density of receptors per cell
can be substantially higher than in native tissues with
the potential for false positives.
A. Class A
1. GPR1 and Chemerin. On the basis of its homology
to CMKLR1, Barnea et al. (2008) identified chemerin
(IUPHAR-DB ID no. 2945) as a GPR1 ligand using
a b-arrestin assay. An iodinated C-terminal peptide
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fragment of chemerin (149–157 amino acids of full-length
chemerin; chemerin C-terminal peptide; IUPHAR-DB ID
no. 3422) bound to GPR1-transfected cells with a single
binding site (Kd of 5.3 nM), similar to the Kd of 4.9 nM
for CMKLR1-transfected cells. However, in a b-arrestin
recruitment assay, chemerin had an EC50 of 240 pM at
GPR1 compared with 3 nM for CMKLR1. A C-terminal
peptide fragment, chemerin 145–157, also bound to
GPR1 in a b-arrestin assay (Southern et al., 2013).
Chemerin also binds to CCRL2 (see below; Leick et al.,
2010), which is thought to be a nonsignaling receptor
that functions to reduce the local concentration of the
molecule (Zabel et al., 2008).
2. GPR3/GPR6/GPR12 and Sphingosine 1-Phosphate.
Currently, there are five lysophospholipid receptors,
which have been classified as S1P1–S1P5 receptors
because their endogenous ligand is accepted to be
the lysophospholipid sphingosine 1-phosphate (S1P;
IUPHAR-DB ID no. 911). GPR3, GPR6, and GPR12 are
phylogenetically related to the S1P, LPA, and melano-
cortin receptors (Gloriam et al., 2007). They were pro-
posed to be three additional S1P receptors following
screening of 200 bioactive lipids (Uhlenbrock et al.,
2002), but this result was not replicated in a b-arrestin-
based assays by two different groups (Yin et al., 2009,
Southern et al., 2013). S1P was also suggested to be a
high-affinity ligand forGPR6 in a study by Ignatov et al.
(2006). All three receptors display significant constitutive
activation of adenylate cyclase (through Gs) and calcium
mobilization (through Gi), which can be modulated by
S1P and dihydrosphingosine 1-phosphate (IUPHAR-DB
ID no. 2921) with nanomolar EC50 values.
3. GPR4/GPR65/GPR68/GPR132 (G2A) and Protons.
In biological systems, carbon dioxide exists in equilib-
rium with bicarbonate and protons (H+), which must be
sensed to be able to maintain cellular pH. The cluster
of structurally related GPCR genes encoding GPR4
(Ludwig et al., 2003; Tobo et al., 2007), GPR65 (Wang
et al., 2004), GPR68 (Ludwig et al., 2003), and GPR132
(Murakami et al., 2004) have been proposed to function
as proton-sensing receptors detecting acidic pH (Seuwen
et al., 2006). This family was originally reported to
respond to lipids such as sphingosylphosphorylcholine,
lysophosphatidylcholine, and psychosine, but these re-
ports have been retracted (Zhu et al., 2001; Witte et al.,
2005) and others have found negative regulation of
these receptors by high micromolar concentrations of
lipids not to be specific (Seuwen et al., 2006). The cur-
rent balance of opinion is in favor of proton sensing. The
physiologic role of this family in sensing pH is beginning
to emerge (Kostenis, 2004; Meyer zu Heringdorf and
Jakobs, 2007). Yang et al. (2007) reported that deletion of
the GPR4 gene in mice leads to partially penetrant
vascular abnormalities during development and specu-
lated that the receptor functions in blood vessel pH
sensing. Gene disruption of GPR4 is also associated with
reduced sensitivity to vascular endothelial growth
factor-evoked angiogenesis (Wyder et al., 2011).
4. GPR17: Dual Receptor for Cysteinyl Leukotrienes/
Nucleotides. GPR17 is phylogenetically related to the
nucleotide (P2Y) and cysteinyl leukotriene (CysLT)
receptors (Gloriam et al., 2007) and may provide an
ancestral link to the two families. Both CysLTs (with
EC50 values in the nanomolar range) and uracil nu-
cleotides (EC50 in the micromolar range) have been
reported to activate GPR17, leading to both adenylyl
cyclase inhibition and intracellular calcium increases
(Ciana et al., 2006). Benned-Jensen and Rosenkilde
(2010) confirmed the activation of GPR17 by uracil
nucleotides but were unable to demonstrate activation
or binding by CysLTs. A third group (Maekawa et al.,
2009) was not able to demonstrate activation of GPR17
by either UDP-glucose or CysLTs and instead proposed
that GPR17 functions as a negative regulator of the
CysLT1 receptor response to leukotriene D4. In vivo
inhibition of GPR17 or in vivo knockdown by antisense
molecules reduced ischemic damage in a rat focal
ischemia model, suggesting that GPR17may be a target
mediating brain damage by nucleotides and CysLTs
(Ciana et al., 2006).
5. GPR18 and N-Arachidonoylglycine, Cannabinoid
Ligands. Kohno et al. (2006) screened a lipid library
and identified an endogenous ligand, N-arachidonoyl-
glycine (NAGly; IUPHAR-DB ID no. 3635) by measur-
ing an increase in intracellular Ca2+ concentration in
GPR18-transfected cells. NAGly also inhibited forskolin-
induced cAMP production in a pertussis toxin–sensitive
manner in the GPR18-transfected CHO cells, with an
EC50 value of 20 nM. GPR18 is mainly expressed in
lymphoid cell lines, such as spleen and thymus, with
moderate expression in brain, testis, ovary, and lung,
and the authors suggested that GPR18 might be
involved in regulation of the immune system. NAGly has
been suggested to be an endogenous metabolite of the
endocannabinoid anandamide (N-arachidonoyl ethanol-
amine; IUPHAR-DB ID no. 2364), differing only in
a change in the oxidation state of the carbon b to the
amido nitrogen that greatly reduces agonist activity at
cannabinoid receptors CB1 and CB2. NAGly is present in
a range of tissues including skin, small intestine, kidney,
and testis and displays distinct antinociceptive and anti-
inflammatory activities. McHugh et al. (2010) have
suggested that NAGly mediates these actions via
a putative “abnormal cannabidiol” receptor, which is
GPR18. More recently, GPR18 has been confirmed to
respond to NAGly (McHugh et al., 2012) but also to the
prototypic CB1 and CB2 cannabinoid receptor ligand,
D9-tetrahydrocannabinol (IUPHAR-DB ID no. 2424). In
contrast, the pairing of NAGly and D9-tetrahydrocan-
nabinol could not be repeated in a b-arrestin assay
(Southern et al., 2013). The nomenclature of GPR18 is
currently being considered by the cannabinoid receptor
subcommittee of NC-IUPHAR.
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6. GPR31 and 12-(S)-Hydroxyeicosatetraenoic Acid.
12-(S)-Hydroxyeicosatetraenoic acid [12-(S)-HETE;
IUPHAR-DB ID no. 3404] is a 12-lipoxygenase metab-
olite of arachidonic acid (IUPHAR-DB ID no. 2391),
which produces a number of cellular responses in-
cluding cytoskeletal remodeling to facilitate cell che-
motaxis and secretion of proteinases and vascular
endothelial growth factor leading to an angiogenic
response. 12-(S)-HETE treatment of cancer cells also
enhanced the expression of integrins and fibronectin,
which prolong cell survival. GPR31 displayed high-
affinity binding for tritiated 12-(S)-HETE (Kd = 5 nM),
and unlabeled 12-(S)-HETE stimulated guanosine 59-3-
O-(thio)triphosphate coupling in the membranes of
GPR31-transfected cells, with an EC50 of 0.28 nM
(Guo et al., 2011). In concordance, GPR31 is phylo-
genetically closest to the OXE receptor (for which
the ligand is 5-oxo-6,8,11,14-eicosatetraenoic acid;
IUPHAR-DB ID no. 3391) (Gloriam et al., 2007).
7. GPR32 and Resolvin D1. By use of a b-arrestin
assay, Krishnamoorthy et al. (2010) demonstrated that
resolvin D1 (RvD1; IUPHAR-DB ID no. 3934), which is
produced physiologically from the oxidation of docosa-
hexaenoic acid (IUPHAR-DB ID no. 1051), had a
remarkably high EC50 value of 4 pM. The aspirin-
triggered epimer of RvD1 (AT-RvD1) and stable
synthetic analogs 17(R/S)-methyl RvD1 and RvD1-
ME were equally potent. These compounds also stimu-
lated b-arrestin binding in cells expressing recombinant
human formyl peptide receptors ALX/FPR2 (ALX/
FPR2 is also considered a lipoxin A4 receptor and
thought to bind peptides and two classes of lipids, the
lipoxins and resolvins). Krishnamoorthy et al. (2012)
suggest that RvD1 mediates the resolution of acute
inflammation by interaction with these two receptors.
Resolvin D5 has been reported to activate GPR32 by
Chiang et al. (2012). In contrast, the pairing of RvD1
with GPR32 could not be repeated in a recent b-arrestin
assay (Southern et al., 2013).
8. GPR34 and Lysophosphatidylserine. GPR34 is
phylogenetically related to the P2Y receptor family
(Gloriam et al., 2007). Lysophosphatidylserine (LysoPS;
IUPHAR-DB ID no. 4064) is thought to function as an
immunologic regulator as it augments the degranula-
tion of peritoneal mast cells where GPR34 is abundantly
expressed. LysoPS caused a pertussis toxin–sensitive
decrease in the cAMP level of CHO cells expressing
GPR34, with an EC50 value of 270 nM. These cells did
not respond to structurally related phospholipids
examined, including lysophosphatidylethanolamine,
lysophosphatidylcholine, LPA, S1P, and phosphati-
dylserine (Sugo et al., 2006). LysoPS has also been
reported as the activating ligand by others (Iwashita
et al., 2009; Kitamura et al., 2012), with the suggestion
that the receptor prefers fatty acid substitution in the
sn-2 position (Kitamura et al., 2012). In contrast, in
a detailed phylogenetic study, Ritscher et al. (2012)
concluded that LysoPS had no or very weak agonistic
activity at most vertebrate GPR34 orthologs investi-
gated and that the search for the endogenous agonist
should consider additional chemical entities.
9. GPR35 and Kynurenic Acid/2-Acyl Lysophospha-
tidic Acid. Wang et al. (2006a) first reported that
kynurenic acid (IUPHAR-DB ID no. 2918) was an agonist
of GPR35; this observation has since been replicated in
functional assays releasing interleukin 4 (Fallarini et al.,
2010) and in a b-arrestin assay (Southern et al., 2013),
but controversy remains whether the endogenous ligand
reaches sufficient tissue concentrations to activate the
receptor (Kuc et al., 2008). 2-Acyl lysophosphatidic acid
(2-oleoyl-LPA; IUPHAR-DB ID no. 2936) has also been
proposed as an endogenous ligand (Oka et al., 2010b).
Zaprinast (IUPHAR-DB ID no. 2919), a cyclic GMP-
selective phosphodiesterase (PDE5A/PDE6) inhibitor, is
reported to be an agonist for GPR35 (Taniguchi et al.,
2006). GPR35 is also activated by the loop diuretic drugs
bumetanide (IUPHAR-DB ID no. 4837) and furosemide
(frusemide; IUPHAR-DB ID no. 4839) (Yang et al., 2012),
the pharmaceutical adjunct pamoic acid (IUPHAR-DB
ID no. 2920) (Neubig, 2010; Zhao et al., 2010), gallic acid,
wedelolactone (Deng et al., 2012), D-luciferin (Hu et al.,
2012), and multiple metabolites of tyrosine (IUPHAR-DB
ID no. 4791) (Deng et al., 2012), but it is unclear whether
these compounds are selective for this receptor.
10. GPR37 and Neuropeptide Head Activator.
The neuropeptide head activator (IUPHAR-DB ID no.
2496), originally isolated from the freshwater coelen-
terate hydra (Hydra attenuata), is a mitogen for all
types of cells in Hydra as well as mammalian cell lines
of neuronal or neuroendocrine origin. Electrophysio-
logical recordings in frog oocytes and in mammalian
cell lines as well as Ca2+ mobilization assays revealed
nanomolar affinities (EC50 value of 3 nM) for activation
of GPR37. An inhibitory G protein-mediated signal
transduction and treatment with head activator resulted
in internalization of GPR37. Overexpression of GPR37
led to aggregate formation, retention of the receptor in
the cytoplasm, and low survival rates of transfected cells,
leading to the suggestion that misfolded GPR37 contrib-
utes to the cell death that can be detected in conditions
such as Parkinson’s disease (Rezgaoui et al., 2006).
GPR37 has been reported to associate with and
regulate the dopamine transporter, while gene disrup-
tion results in altered striatal signaling (Marazziti
et al., 2007, 2011). Although the isolation of a peptide
of identical amino acid sequence to Hydra head
activator from human hypothalamus, bovine hypothal-
amus, and rat intestine has been reported (Bodenmuller
and Schaller, 1981), its existence in mammals is un-
clear because there is currently no evidence for the
presence of a precursor gene for this peptide in any
sequenced genome. However, it is possible that the
precursor protein may lie within an unsequenced part
of the genome. Interestingly, GPR37 overexpression in
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HEK cells can induce cellular autophagy, which may
prevent the selective degeneration of GPR37-expressing
neurons, as reported for Parkinson’s and related neuro-
degenerative diseases (Marazziti et al., 2009). The pairing
of GPR37 with neuropeptide head activator could not be
replicated in a recent b-arrestin assay (Southern et al.,
2013).
11. GPR39 and Zn2+ but Retraction of Obestatin as
Cognate Ligand. The initial reported pairing of GPR39
with the novel peptide obestatin (IUPHAR-DB ID no.
5336), derived from the precursor of the appetite-
stimulating hormone ghrelin (Zhang et al., 2005), could
not be repeated; [125I]Obestatin did not bind GPR39, and
obestatin was without action on GPR39-transfected cells
in various functional assays (cAMP production, calcium
mobilization, and GPR39 internalization) (Lauwers et al.,
2006; Chartrel et al., 2007; Holst et al., 2007; Tremblay
et al., 2007). Zhang et al. (2007) have since confirmed that
they could not reproduce their findings on obestatin
binding and activation of GPR39 receptors in vitro. The
results they originally obtained may have been caused by
contamination of the sample of obestatin by impurities
and loss of binding by the labeled analog as a result of
labeling with iodine. The authors are to be commended
for publishing the reasons for being unable to repeat their
original study. Zn2+ ions have since been proposed as the
cognate ligand (Holst et al., 2007; Yasuda et al., 2007;
Sharir et al., 2010; Popovics and Stewart, 2011). There
are conflicting reports concerning the effects of disruption
of GPR39 on body weight (Moechars et al., 2006;
Tremblay et al., 2007). The receptor is expressed in
pancreatic b cells, and there is evidence for a role of
GPR39 in the regulation of glucose homeostasis
(Petersen et al., 2011).
As described above, a significant number of pairings
of GPCRs with putative endogenous ligands are cur-
rently supported by a single paper and await indepen-
dent confirmation by other groups. A number of pairings
have been formally retracted. For example, the reported
pairing ofGPR39 by obestatin (IUPHAR-DB ID no. 5336)
(Zhang et al., 2005) could not be repeated in various in
vitro assays (Chartrel et al., 2007). Nevertheless, more
than 50 papers have subsequently described the physi-
ologic and pharmacological actions of the peptide, in-
cluding acting as an anorectic hormone, decreasing food
intake, reducing body weight gain, regulating sleep, and
affecting cell proliferation. To date, no alternative receptor
or transducing mechanism has been identified.
12. GPR55 and Lysophosphatidylinositol. GPR55
was identified as an orphan GPCR abundantly expressed
in human caudate nucleus and putamen but not in hip-
pocampus, cerebellum, frontal cortex, or liver (Sawzdargo
et al., 1999). A number of reviews have highlighted the
confusion arising from studies investigating the pharma-
cology of GPR55 (Godlewski et al., 2009; Ross, 2009,
2011; Pertwee et al., 2010; Sharir and Abood, 2010). It is
unclear why there are discrepancies between different
laboratories, although it may be that the use of distinct
host cells with distinct repertoires of potential signaling
partners and the analysis of distinct signaling path-
ways may contribute to the variation in agonist pro-
files. From these studies, however, a certain level of
consensus has been attained identifying lysophospha-
tidylinositol (LPI; IUPHAR-DB ID no. 4028) as an
endogenous agonist (Oka et al., 2007). The activation of
GPR55 by LPI has been described by numerous groups
(Lauckner et al., 2008; Waldeck-Weiermair et al., 2008;
Henstridge et al., 2009, 2010; Kapur et al., 2009; Whyte
et al., 2009; Yin et al., 2009; Bondarenko et al., 2010;
Ford et al., 2010; Oka et al., 2010a; Ishiguro et al., 2011;
Pineiro et al., 2011; Southern et al., 2013). Commercially
available LPI is primarily plant-derived, containing mix-
tures of fatty acid substituents with amajority of medium-
chain saturated and monounsaturated fatty acids at the
1-position of LPI (Oka et al., 2009). It has been suggested
that a 2-isomer of LPI, 2-arachidonoyl-sn-glycero-3-
phosphoinositol (arachidonoyl LPI; IUPHAR-DB ID
no. 4029), present at levels similar to the endogenous
cannabinoid 2-arachidonoylglycerol (IUPHAR-DB ID no.
729) (Sugiura et al., 1995; Artmann et al., 2008; Oka
et al., 2009), is a more realistic candidate for an en-
dogenous GPR55 ligand (Oka et al., 2009). The biologic
activity of 2-arachidonoyl LPI was markedly higher
than those of other molecular species of LPI tested as
activators of extracellular signal–regulated kinase (ERK)
or elevation of intracellular calcium ions in heterolo-
gous expression studies of GPR55 (Oka et al., 2009). It
should be noted, however, that LPI has actions in-
dependent of GPR55, in inhibiting the plasma mem-
brane Na+/K+-ATPase (Bondarenko et al., 2010) and
regulating endothelial cell BKCa channels, allowing
an enhancement of activity at times when the channel
activity was low and reducing channel activity at higher
levels of channel stimulation (Bondarenko et al., 2010).
The nomenclature of GPR55 is currently under con-
sideration by the cannabinoid receptor subcommittee of
NC-IUPHAR.
13. GPR75 and CCL5 (RANTES). A single paper re-
ports that the chemokine CCL5 (RANTES; IUPHAR-DB
ID no. 758) stimulates Ca2+ mobilization and inositol
trisphosphate formation in cells transfected with GPR75
(Ignatov et al., 2006). However, the pairing of CCL5 and
GPR75 could not be repeated in a recent b-arrestin as-
say (Southern et al., 2013).
14. GPR84 and Medium-Chain FFAs. A single paper
has reported the pairing of medium-chain FFAs with
carbon chain lengths of 9–14 with GPR84 (Wang et al.,
2006b). Medium-chain FFAs mediated calcium mob-
ilization, inhibited cAMP production, and stimulated
[35S]GTP binding via a pertussis toxin–sensitive Gi/o
pathway. GPR84 is expressed in leukocytes and induced
in monocytes/macrophages upon activation by lipopoly-
saccharide, stimulating proinflammatory cytokines, sug-
gesting that GPR84 may link fatty acid metabolism to
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immunologic regulation (Wang et al., 2006b). GPR84 is
highly expressed in the bone marrow, and T cells from
GPR84 knockout mice displayed augmented interleukin-
4 production in response to stimulation with anti-CD3,
suggesting a role for GPR84 in regulating early
interleukin-4 gene expression in activated T cells
(Venkataraman and Kuo, 2005). Currently there is
insufficient evidence to recommend that GPR84 be
classified as FFA5.
15. GPR87 and LPA. A single paper reports that in
CHO cells stably expressing GPR87 fused with Ga16
protein, LPA (IUPHAR-DB ID no. 2906) induced tran-
sient increases in intracellular Ca2+, with a low EC50
value of 40 nM. Calcium increases were blocked by LPA
receptor antagonists and by RNA silencing of GPR87.
GPR87 was shown to be more closely related to the P2Y
and P2Y-related receptors than to LPA receptors (Nonaka
et al., 2005), but none of the nucleotides or their deri-
vatives activated GPR87 (Tabata et al., 2007).
16. GPR119 and Derivatives of Oleate. GPR119 is
expressed in pancreatic b cells and the gastrointestinal
tract and appears to be activated by multiple deriva-
tives of the medium-chain monounsaturated fatty acid
oleate (IUPHAR-DB ID no. 1054), including lysophos-
phatidylcholine (IUPHAR-DB ID no. 2508) (Soga et al.,
2005), N-oleoylethanolamine (IUPHAR-DB ID no. 2661)
(Overton et al., 2006, Ning et al., 2008; Southern et al.,
2013), N-oleoyldopamine (Chu et al., 2010), and 2-
oleoylglycerol (IUPHAR-DB ID no. 5112) (Hansen et al.,
2011).
When fed a low-fat diet, GPR119 knockout mice had
normal plasma glucose and lipids but lower body weights
and lower postprandial levels of GLP-1. Nutrient-
stimulated GLP-1 release was attenuated (Lan et al.,
2009). GPR119 has evolved into a potential target for the
next generation of compounds to treat type 2 diabetes
mellitus, with numerous publications describing syn-
thetic ligands, some of which are commercially avail-
able. Both the preclinical and clinical data suggest
that GPR119 agonists will be promising antidiabetic
drugs (Shah and Kowalski, 2010). The nomenclature of
GPR119 is currently being considered by the cannabinoid
receptor subcommittee of NC-IUPHAR.
17. GPR182 and Adrenomedullin. Kapas et al. (1995)
reported thatGPR182 was a receptor for adrenomedullin
(IUPHAR-DB IDs nos. 683, 697, 3589), but Kennedy
et al. (1998) failed to replicate this finding, and therefore,
the endogenous ligand of this receptor remains unknown.
18. GPR183 (EBI2) and Oxysterols. Two indepen-
dent reports (Hannedouche et al., 2011; Liu et al.,
2011) have proposed oxysterols as ligands for GPR183.
Liu et al. (2011) isolated oxysterols from porcine spleen
extracts and demonstrated that 7a,25-dihydroxycholes-
terol (7a,25-OHC; IUPHAR-DB ID no. 4350) was the
most potent endogenous ligand of this receptor, with a
Kd of 450 pM. 7a,25-OHC is synthesized from cholesterol
by the sequential action of cholesterol 25-hydroxylase
and CYP7B1 (25-hydroxycholesterol 7-a-hydroxylase).
Consistent with 7a,25-OHC as an endogenous ligand,
inhibition of CYP7B1 with clotrimazole reduced the
content of 7a,25-OHC in the mouse spleen and mimicked
the phenotype of preactivated B cells from gpr183-
deficient mice (Liu et al., 2011), and mice deficient in
cholesterol 25-hydroxylase had a similar phenotype to
GPR183 knockout mice (Hannedouche et al., 2011).
Oxysterols can affect immune and inflammatory re-
sponses as well as cholesterol metabolism, and these
effects are normally thought to be by via nuclear hormone
receptors rather than a GPCR.
19. P2Y10 and S1P/LPA. The gene encoding
P2Y10 (P2RY10) was originally named on the basis of
sequence similarity to other P2Y receptors, but sub-
sequent phylogenetic analyses have shown that P2Y10 is
most closely related in sequence to receptors for platelet-
activating factor (IUPHAR-DB ID no. 1831) and LPA
(IUPHAR-DB ID no. 2906) (Gloriam et al., 2007). S1P
(IUPHAR-DB ID no. 911) and LPA stimulated increases
in intracellular Ca2+ in CHO cells stably expressing
P2Y10 fused with a Ga16 protein, with EC50 values of 53
and 130 nM, respectively (Murakami et al., 2008). These
responses were blocked by S1P and LPA receptor
antagonists and by RNA silencing of P2Y10 in these
cells. In mice, P2Y10 was widely expressed, including in
reproductive organs, brain, lung, and skeletal muscle.
The authors concluded that P2Y10 is a dual lysophos-
pholipid receptor, but it has not yet been accepted as an
LPA receptor by NC-IUPHAR.
20. MAS1 and Angiotensin-(1-7). Angiotensin-converting
enzyme 2 metabolizes angiotensin II (IUPHAR-DB ID
no. 2504) to angiotensin-(1-7) [Ang-(1-7), IUPHAR-DB
ID no. 582], which functions as a vasodilator and anti-
proliferative agent. Santos et al. (2003) first provided
evidence that some of the actions of Ang-(1-7) are
mediated via the MAS1 receptor. Ang-(1-7) bound to
MAS1-transfected cells and elicited arachidonic acid
(IUPHAR-DB ID no. 2391) release. Deletion of theMas1
gene in mice abolished the binding of Ang-(1-7) in mouse
kidney and abolished the antidiuretic action of the
peptide after an acute water load (Santos et al., 2003).
Mas1-deficient mouse aortas lost Ang-(1-7)-induced re-
laxation responses. For further information on the effect
of deleting the MAS1 receptor, see Alenina et al. (2008).
21. LGR4, LGR5, and LGR6 and R-Spondins.
LGR4, LGR5, and LGR6 were first identified as a family
of structurally distinct seven-transmembrane receptors
with homology to glycoprotein hormone receptors (Hsu
et al., 1998, 2000). R-spondins (IUPHAR-DB ID nos.
3697, 3698, 3699, 3700, 4383) are a group of secreted
proteins that enhance Wnt/b-catenin signaling, which
plays essential roles in embryonic development and in
the self-renewal and maintenance of adult stem cells.
Carmon et al. (2011) demonstrated that LGR4 and LGR5
bind the R-spondins with high affinity and mediate the
potentiation of Wnt/b-catenin signaling by enhancing the
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phosphorylation of the Wnt coreceptor LRP6. Gong et al.
(2012) showed that LGR6 also binds and responds to
R-spondins, and de Lau et al. (2011) reported that each of
the four R-spondins can bind to LGR4, LGR5, and LGR6.
However, these receptors do not couple to G proteins or
to b-arrestin, suggesting that they do not function as
conventional GPCRs (Gong et al., 2012). LGR5 is a
marker of stem cells in the base of intestinal crypts and
in hair follicles; significant data support LGR5+ stem
cells as cells of origin for colorectal carcinoma and also
implicate LGR5 as a mediator of tumor aggression (Kleist
et al., 2011).
22. Mas-Related GPCRs: MRGPRD with b-Alanine;
MRGPRX1 with Bovine Adrenal Medulla Peptide 22
(BAM22); MRGPRX2 with Cortistatin-14. Of the eight
human Mas-related GPCRs (MRGs), four (MRGPRD,
MRGPRE,MRGPRF, andMRGPRG) have clear orthologs
in rodents, whereas the cluster of genes including human
MRGPRX1, MRGPRX2, MRGPRX3, and MRGPRX4 is
found only in primates and is replaced in rodents with
a family of genes (.25 in mice; ;10 in rats) that have no
obvious human counterparts (Dong et al., 2001). Cer-
tain rodent MRGs have been reported to respond to
adenine (Bender et al., 2002) and to RF-amide pep-
tides including neuropeptide FF (Han et al., 2002; Lee
et al., 2008a), but the relevance of these findings to
man is unclear. MRGs are expressed predominantly
in small-diameter sensory neurons of the dorsal root
ganglia, where there is emerging evidence that they
may be mediators of histamine-independent itch (Liu
et al., 2009; Wilson et al., 2011).
b-Alanine (IUPHAR-DB ID no. 2365) induced the
rapid mobilization of intracellular Ca2+ in CHO cells
expressing human, rat, or mouse MRGPRD (TGR7) in
a concentration-dependent manner, with EC50 values of
15, 14, and 44 mM, respectively (Shinohara et al., 2004).
Responses to b-alanine were pertussis toxin–sensitive
(Shinohara et al., 2004; Crozier et al., 2007). b-Alanine
activated MRGPRD in a b-arrestin assay with a similar
EC50 value of 15 mM (Southern et al., 2013). [
3H]b-Alanine
bound toMRGPRD-expressing CHO cells, but compounds
structurally related to b-alanine, including L-glycine
(IUPHAR-DB ID no. 727), L-alanine (IUPHAR-DB
ID no. 720), taurine (IUPHAR-DB ID no. 2379), and
L-anserine, did not stimulate intracellular calcium. Milasta
et al. (2006) also demonstrated that cells expressing
MRGPRD responded to b-alanine. There was evidence
that responses to b-alanine (elevations of intracellular
Ca2+, phosphorylation of mitogen-activated protein
kinases ERK1 and ERK2, and receptor internalization)
could be modulated by the formation of heterodimers
with MRGPRE (Milasta et al., 2006).
Bovine adrenal medulla peptide 22 (BAM22) is a
C-terminally extended form of Met-enkephalin pro-
duced by proteolytic cleavage of the opioid peptide
precursor proenkephalin A. Lembo et al. (2002) found
that BAM22 was the most potent compound evoking a
concentration-dependent release of intracellular cal-
cium in cells stably expressing the human MRGPRX1
(which they called sensory neuron2specific receptor 3 or
SNSR3), with an EC50 value of 13 nM. Many of the
classic opioid peptides were inactive at MRGPRX1, and
classic opioid antagonists such as naloxone were inactive
as antagonists. Chen and Ikeda (2004) and Solinski
et al. (2010) confirmed that BAM22 is an agonist of
MRGPRX1, and this has been replicated in a b-arrestin
assay (Southern et al., 2013). Chloroquine, an antima-
larial drug that frequently produces itch as a side effect,
activates MRGPRX1, consistent with a possible role for
this receptor in mediating histamine-independent itch
(Liu et al., 2009).
Robas et al. (2003) reported that cortistatin-14 (IUPHAR-DB
ID no. 2007), a neuropeptide related to somatostatin but
encoded by a different gene (de Lecea et al., 1996),
stimulated intracellular calcium in cells expressing
human MRGPRX2, with an EC50 of 25 nM. A number
of other cyclic peptides showed high nanomolar potency.
Kamohara et al. (2005) confirmed this pairing but also
found that the endogenous peptides proadrenomedullin
N-terminal 20 peptide (PAMP-20; IUPHAR-DB ID
no. 4057) and its N-terminally truncated analog,
PAMP-12 (IUPHAR-DB ID no. 4056), also activated
the receptor with a similar potency in calcium mobiliza-
tion. Cortistatin-14 was also shown to bind toMRGPRX2
in a b-arrestin assay (Southern et al., 2013).
MRGPRX2 coupled with Gq and Gi. Nothacker et al.
(2005) showed in structure-activity studies that both
cortistatin and PAMP bind to and activate MRGPRX2
at the same binding site owing to a common internal
structural motif that is centered around an octapeptide
that alternates aromatic and basic amino acids, and
both peptides were proposed as surrogate ligands for
this receptor. NonpeptideMRGPRX2 receptor agonists
have been identified (Malik et al., 2009).
B. Class B
All of the orphans in this subfamily are called adhesion
receptors in some classifications (see, for example,
Lagerström and Schioth, 2008); a defining feature of this
subfamily is the presence of a GPCR proteolytic site-
containing stalk region. None of the following putative
ligands has been demonstrated to signal through con-
ventional G protein-coupled mechanisms (although see
GPR56 below).
1. BAI1 and Phosphatidylserine. A single paper
reports phosphatidylserine (IUPHAR-DB ID no. 3638)
as a ligand for BAI1, which has a role in the engulfment
and subsequent degradation of apoptotic cells (Park
et al., 2007; reviewed in Bratton and Henson, 2008).
2. BAI3 and C1q-like Proteins. C1q-like proteins
are small, secreted proteins of unknown function that
are synthesized from four genes in mammals, expressed
almost exclusively in brain, and produced in differential
patterns by specific types of neurons. According to one
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report, C1q-like proteins bind to the extracellular
thrombospondin-repeat domain of BAI3 with high
affinity and act, at least in part, to regulate synapse
formation and/or maintenance (Bolliger et al., 2011).
3. CD97 and Decay Accelerating Factor. Several
groups have reported that decay accelerating factor
(CD55), a regulatory protein of the complement cascade,
is a ligand of CD97 (Hamann et al., 1996; Qian et al.,
1999; Lin et al., 2001). Thy-1 (CD90) has been reported to
bind to CD97, and this interaction has been proposed
to play a role in the regulation of leukocyte trafficking
by facilitating adhesion of polymorphonuclear cells to
activated endothelial cells (Wandel et al., 2012). Chon-
droitin sulfate has been reported to be a ligand of both
CD97 and EMR2 (Stacey et al., 2003).
4. GPR56 and Collagen Type III. Collagen, type III,
a-1 (gene symbol, COL3A1) has been proposed as the
ligand of GPR56 (Luo et al., 2011), signaling by activating
RhoA through coupling to G12/13. Transglutaminase 2,
a major crosslinking enzyme in the extracellular matrix,
has also been proposed as a ligand of GPR56 (Xu and
Hynes, 2007).
5. LPHN1 and LPHN3. The massive synaptic
exocytosis caused by the black widow spider venom
a-latrotoxin is thought to be due to toxin binding to two
distinct receptor families: the latrophilin group of class B
GPCRs (LPHN1, -2, and -3) and the neurexins (neurexin-
1, -2, and -3), which are presynaptic membrane proteins.
LPHN1 has been proposed to be a ligand of neurexins,
producing a stable intercellular adhesion complex (Boucard
et al., 2012). Lasso, a splice variant of teneurin-2, a
brain-specific orphan cell surface receptor with a
function in neuronal pathfinding and synaptogenesis
(Silva et al., 2011) and FLRT3, a member of the FLRT
family of leucine-rich repeat transmembrane proteins
(O’Sullivan et al., 2012), have been reported to be
endogenous postsynaptic ligands for LPHN1 and LPHN3,
respectively.
C. Class C
1.GPRC6A and Calcium, Amino Acids, and Osteocalcin.
GPRC6A has been reported to sense both nutrient-
derived factors, such as calcium and amino acids
(Christiansen et al., 2007; Pi et al., 2012); testoster-
one (Pi et al., 2010); and the bone-derived hormone
osteocalcin (Oury et al., 2011; Pi et al., 2011).
V. Orphan Receptors with Activity in Absence of
an Endogenous Ligand, Activation by Surrogate
Ligands, or Significant Phenotype in Genetically
Modified Animals
Although ligands for orphan GPCRs continue to be
identified, there is also evidence that some may have
functions in the absence of an endogenous transmitter
through constitutive activity or by modulating the
activity of other GPCRs via dimerization. These
receptors may still represent a druggable target by the
discovery of synthetic (“surrogate”) ligands. Other seven-
transmembrane receptors may not signal via conven-
tional pathways such as G proteins but still function to
modulate the actions of transmitters.
A. Constitutively Active GPCRs. Constitutive activ-
ity is defined by receptor signaling in the absence of
a ligand and has mainly been detected using in vitro
studies measuring downstream signaling, which may
be reduced by the action of inverse agonists. Constitutive
activity has been reported for a number of established
receptors and in many cases characterized further by the
use of inverse agonists. Constitutive activity has been
reported in a number of orphan receptors, but it does not
necessarily mean that an endogenous ligand does exist:
Ligands acting at a constitutively active receptor can act
as agonists, antagonists, and/or inverse agonists. Sec-
ondly, there is no formal definition of what magnitude of
basal signaling in the absence of a ligand constitutes
intrinsic activity. However, the existence of constitutive
activity, particularly when caused by amino acid muta-
tions or other variants, combined with the development
of inverse agonists at these receptors has the potential
for new strategies for drug development, and with the
above caveats, we have highlighted this information
where it exists in the literature. Constitutive activity has
been reported for EBI2 (Rosenkilde et al., 2006), GPR3
(Eggerickx et al., 1995), GPR6 (Uhlenbrock et al., 2002),
GPR12 (Uhlenbrock et al., 2002), GPR17 (Benned-
Jensen and Rosenkilde, 2010), GPR18 (Qin et al., 2011),
GPR20 (Hase et al., 2008), GPR22 (Adams et al., 2008),
GPR26 (Jones et al., 2007), GPR39 (Holst et al., 2004),
GPR61 (Toyooka et al., 2009), GPR78 (Jones et al., 2007),
and MAS1 (Canals et al., 2006).
B. C5AR2 (GPR77, C5L2). C5AR2 (Klos et al.,
2013) is the first example of a naturally occurring
seven-transmembrane segment receptor that is both
obligately uncoupled from G proteins and a negative
modulator of signal transduction through the b-arrestin
pathway (Bamberg et al., 2010).
C. CCRL1 (CCX-CKR), CCRL2 (CRAM), CCBP2 (D6),
and DARC. These proteins do not appear to couple to G
proteins or, in some cases, do not signal through defined
pathways. They could all be considered as chemokine
binding proteins or "scavengers" that remove chemokines
from the local environment, but there is no consensus and
no systematic classification can be currently justified.
CCRL2 is thought to be a nonsignaling receptor that
binds chemerin (IUPHAR-DB ID no. 2945) and increases
the local concentration of the peptide (Zabel et al., 2008).
The nomenclature of this family of receptors, which
also includes CXCR7 (CMKOR1; see section III.A.5 for
further information), is currently being considered by
the chemokine receptor subcommittee of NC-IUPHAR.
D. GPR50 Is a Negative Regulator of MT1 and MT2.
GPR50 (melatonin-related receptor) is structurally
related to the melatonin receptors, MT1 and MT2, but
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does not bind melatonin, and its endogenous ligand has
not been identified. GPR50 heterodimerizes constitu-
tively and specifically with MT1 to abolish high-affinity
agonist binding and G protein coupling. Although
GPR50 also heterodimerizes with MT2, this had no
effect on function and MT2 in intact cells (Levoye et al.,
2006).
GPR50 knockout mice showed resistance to diet-
induced obesity but lost less weight than wild-type mice
when fasted (Ivanova et al., 2008). The mice entered
torpor muchmore readily than wild-type mice in response
to fasting or 2-deoxyglucose administration and displayed
attenuated responses to leptin and a suppression of
thyrotropin-releasing hormone (Bechtold et al., 2012).
VI. Pseudogenes
Pseudogenes are genomic DNA sequences that display
homology to known functional genes but that during the
course of evolution acquired mutations that render them
nonfunctional. This is often thought to occur when a gene
is duplicated and the new copy has an evolutionary
window within which it can acquire new functions leading
to its preservation, or deleterious mutations may accu-
mulate so that function is irreversibly lost. Thus, a given
gene can be functional in some species but not in others.
Inactivating mutations can be anywhere in the gene and
lead to loss of function at the levels of gene transcription,
pre-mRNA processing, translation, or protein folding. The
most readily identified disablements are stop codons and
frameshifts.
It is fairly obvious that a gene is a pseudogene when
it has acquired numerous premature termination codons
or shifts in reading frame. NC-IUPHAR has not been
concerned about such obvious pseudogenes. However,
there are a number of borderline cases that should be
considered since our perception of whether they are
functional is subject to change. These cases typically have
a single mutation leading to a truncated receptor protein.
Indeed, there are several cases in which the mutation is
now known to be polymorphic, so that the gene appears to
be functional in some portion of the human population.
A. GPR33. GPR33 is phylogenetically related to the
chemerin receptor (CMKLR1) and GPR1 and has been
proposed to function as a chemoattractant receptor
(Rompler et al., 2005). It was listed as a functional gene
in Foord et al. (2005) but is inactivated by a premature
termination codon in a number of species (Rompler
et al., 2005). GPR33 appears to be a pseudogene
in most individuals, with a premature stop codon
at amino acid 140 in the second cytoplasmic loop
(Rompler et al., 2005; Bohnekamp et al., 2010; Zhang
et al., 2010). According to the National Center for
Biotechnology Information dbSNP database (Sherry
et al., 2001), this polymorphism, rs17097921, gives the
truncated allele in 100% of Europeans but an active
Arg140 allele in 2–8% of Asians and Africans.
B. TAAR2 and TAAR9. Two of the trace amine recep-
tors are inactivated in a portion of the human popula-
tion. There is a polymorphism in TAAR2 (rs8192646)
producing a premature stop codon at amino acid 168 in
10–15% of Asians. TAAR9 (formerly TRAR3) appears to
be functional in most individuals but has a polymorphic
premature stop codon at amino acid 61 (rs2842899) with
an allele frequency of 10–30% in different populations
(Vanti et al., 2003). TAAR3 (formerly GPR57) and TAAR4
(current gene symbol, TAAR4P) are thought to be
pseudogenes in man though functional in rodents
(Lindemann et al., 2005).
C. GPR42. Human GPR42 is closely related to
GPR41 (free fatty acid receptor FFA3) and is thought
to have arisen from a tandem duplication of GPR41 in
the human lineage. Mutagenesis studies have shown
that conversion of arginine 174 in the GPR41 protein to
tryptophan (found in GPR42) abolishes the response
to short-chain fatty acids, raising the possibility that
GPR42 might be a translated but inactive pseudogene
(Brown et al., 2003). It has been proposed that GPR42
could potentially be a functional gene in a significant
fraction of the human population (Liaw and Connolly,
2009), but the very close sequence similarity of GPR41
and GPR42 (six nucleotide differences in the coding
sequence) make this very difficult to assess.
D. GPR79. GPR79 is a full-length gene in both dog
and rodents but is a pseudogene in human (Haitina
et al., 2009).The human EMR4 gene (class B: current
gene symbol, EMR4P) has a single base deletion in the
eighth coding exon compared with other primates and
mouse, leading to the expression of a truncated amino-
terminal domain of 232 amino acids (Hamann et al.,
2003; Caminschi et al., 2006). This protein lacks any of
the transmembrane domains of the EMR4 GPCR from
other species. There is a second open reading frame
capable of encoding a seven-transmembrane GPCR with
a 93-amino-acid amino-terminal domain but there is no
evidence for its translation. Thus, human EMR4 should
be considered as a probable pseudogene, although the
232-amino-acid secreted protein may have biologic
function.
E. GnRH2. In addition to the classic gonadotrophin-
releasing hormone receptor (the GnRH receptor),
some species possess a second GnRH2 receptor. This
gene is absent from the genomes of rats and mice,
but a functional gene is present in some primates;
the human gene was listed as functional in Foord
et al. (2005), but it was subsequently shown that the
human gene contains a frameshift mutation and a
premature stop codon that would result in trans-
lation of a nonfunctional receptor (Morgan et al.,
2003). The neuropeptide Y receptor y6 is a pseudo-
gene in human and pig and is absent in rat but
generates a functional receptor in rabbit and mouse
(Matsumoto et al., 1996; Rose et al., 1997; Starback
et al., 2000).
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VII. Conclusion
Since the original NC-IUPHAR classification of GPCRs
in the human genome (Foord et al., 2005), significant
progress has been made in assigning endogenous ligands,
particularly in class A, and pharmacological tools continue
to be developed to delineate these new transmitter sys-
tems. There is preliminary evidence for pairings of en-
dogenous ligands of 32 GPCRs in class A, 6 in class B, and
1 in class C, but further research is needed to replicate (or
refute) these proposals, particularly as a number of initial
claims have been retracted. Most, if not all, human orphan
receptors have now been expressed in cell lines, but despite
intense effort particularly by the pharmaceutical industry,
there is no public information about the cognate ligand for
a significant number of them. It is possible that the re-
maining receptors may function without ligands by being
constitutively active or by modulating the activity of other
GPCRs, for example, by dimerization (Levoye et al., 2006;
Geng et al., 2012). It is clear from knockout studies in mice
and genetic deletions in man that these receptors may
have a physiological or pathophysiological role and can still
be exploited as drug targets in the absence of an iden-
tifiable ligand. Further information on all the orphan
receptors described in this review can be found on the
IUPHAR Database website at http://www.iuphar-db.org.
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